Joel I. Perez-Perri

Joel I. Perez-Perri

Auto-generated profile, based on publicly available information

Joel I. Perez-Perri

European Molecular Biology Laboratory (EMBL), Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
JPJoel I. Perez-Perri
Joel I. Perez-Perri
BRBirgit Rogell
Birgit Rogell
TSThomas Schwarzl
Thomas Schwarzl
Frank SteinFrank Stein
Frank Stein
YZYang Zhou
Yang Zhou
MHMatthias W. Hentze
Matthias W. Hentze
Following the realization that eukaryotic RNA-binding proteomes are substantially larger than anticipated, we must now understand their detailed composition and dynamics. Methods such as RNA interactome capture (RIC) have begun to address this need. However, limitations of RIC have been reported. Here we describe enhanced RNA interactome capture (eRIC), a method based on the use of an LNA-modified capture probe, which yields numerous advantages including greater specificity and increased signal-to-noise ratios compared to existing methods. In Jurkat cells, eRIC reduces the rRNA and DNA contamination by >10-fold compared to RIC and increases the detection of RNA-binding proteins. Due to its low background, eRIC also empowers comparative analyses of changes of RNA-bound proteomes missed by RIC. For example, in cells treated with dimethyloxalylglycine, which inhibits RNA demethylases, eRIC identifies m6A-responsive RNA-binding proteins that escape RIC. eRIC will facilitate the unbiased characterization of RBP dynamics in response to biological and pharmacological cues.

15 June 2022 in Molecular Cell
Verified
Journal Article
Open access
IHIna Huppertz
Ina Huppertz
JPJoel I. Perez-Perri
Joel I. Perez-Perri
PMPanagiotis Mantas
Panagiotis Mantas
TSThileepan Sekaran
Thileepan Sekaran
TSThomas Schwarzl
Thomas Schwarzl
MHMatthias W. Hentze
Matthias W. Hentze
Differentiating stem cells must coordinate their metabolism and fate trajectories. Here, we report that the catalytic activity of the glycolytic enzyme Enolase 1 (ENO1) is directly regulated by RNAs leading to metabolic rewiring in mouse embryonic stem cells (mESCs). We identify RNA ligands that specifically inhibit ENO1's enzymatic activity in vitro and diminish glycolysis in cultured human cells and mESCs. Pharmacological inhibition or RNAi-mediated depletion of the protein deacetylase SIRT2 increases ENO1's acetylation and enhances its RNA binding. Similarly, induction of mESC differentiation leads to increased ENO1 acetylation, enhanced RNA binding, and inhibition of glycolysis. Stem cells expressing mutant forms of ENO1 that escape or hyper-activate this regulation display impaired germ layer differentiation. Our findings uncover acetylation-driven riboregulation of ENO1 as a physiological mechanism of glycolytic control and of the regulation of stem cell differentiation. Riboregulation may represent a more widespread principle of biological control.

18 November 2020 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
JPJoel I. Perez-Perri
Joel I. Perez-Perri
Marko NoerenbergMarko Noerenberg
Marko Noerenberg
WKWael Kamel
Wael Kamel
CLCaroline E. Lenz
Caroline E. Lenz
SMShabaz Mohammed
Shabaz Mohammed
ACAlfredo Castello
Alfredo Castello

12 April 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JPJoel I. Perez-Perri
Joel I. Perez-Perri
DFDunja Ferring-Appel
Dunja Ferring-Appel
IHIna Huppertz
Ina Huppertz
TSThomas Schwarzl
Thomas Schwarzl
SSSudeep Sahadevan
Sudeep Sahadevan
MHMatthias W. Hentze
Matthias W. Hentze
System-wide approaches have unveiled an unexpected breadth of the RNA-bound proteomes of cultured cells. Corresponding information regarding RNA-binding proteins (RBPs) of mammalian organs is still missing, largely due to technical challenges. Here, we describe ex vivo enhanced RNA interactome capture (eRIC) to characterize the RNA-bound proteomes of three different mouse organs. The resulting organ atlases encompass more than 1300 RBPs active in brain, kidney or liver. Nearly a quarter (291) of these had formerly not been identified in cultured cells, with more than 100 being metabolic enzymes. Remarkably, RBP activity differs between organs independent of RBP abundance, suggesting organ-specific levels of control. Similarly, we identify systematic differences in RNA binding between animal organs and cultured cells. The pervasive RNA binding of enzymes of intermediary metabolism in organs points to tightly knit connections between gene expression and metabolism, and displays a particular enrichment for enzymes that use nucleotide cofactors. We describe a generically applicable refinement of the eRIC technology and provide an instructive resource of RBPs active in intact mammalian organs, including the brain.

1 April 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
YZYang Zhou
Yang Zhou
PRPartho Sarothi Ray
Partho Sarothi Ray
JZJianguo Zhu
Jianguo Zhu
Frank SteinFrank Stein
Frank Stein
MRMandy Rettel
Mandy Rettel
AKAndreas E. Kulozik
Andreas E. Kulozik
Osteosarcoma is the most common primary malignant bone tumor with a strong tendency to metastasize, limiting the prognosis of affected patients. Genomic, epigenomic and transcriptomic analyses have demonstrated the exquisite molecular complexity of this tumor, but have not sufficiently defined the underlying mechanisms or identified promising therapeutic targets. To systematically explore RNA-protein interactions relevant to OS, we define the RNA interactomes together with the full proteome and the transcriptome of cells from five malignant bone tumors (four osteosarcomata and one malignant giant cell tumor of the bone) and from normal mesenchymal stem cells and osteoblasts. These analyses uncover both systematic changes of the RNA-binding activities of defined RNA-binding proteins common to all osteosarcomata and individual alterations that are observed in only a subset of tumors. Functional analyses reveal a particular vulnerability of these tumors to translation inhibition and a positive feedback loop involving the RBP IGF2BP3 and the transcription factor Myc which affects cellular translation and OS cell viability. Our results thus provide insight into potentially clinically relevant RNA-binding protein-dependent mechanisms of osteosarcoma.

10 February 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
JPJoel I. Perez-Perri
Joel I. Perez-Perri
DFDunja Ferring-Appel
Dunja Ferring-Appel
IHIna Huppertz
Ina Huppertz
TSThomas Schwarzl
Thomas Schwarzl
Frank SteinFrank Stein
Frank Stein
MHMatthias W. Hentze
Matthias W. Hentze
Summary: System-wide approaches have unveiled an unexpected breadth of the RNA-bound proteomes of cultured cells. Corresponding information regarding RNA-binding proteins (RBPs) of mammalian organs is still missing, largely due to technical challenges. Here, we describe ex vivo eRIC (enhanced RNA interactome capture) to characterize the poly(A)RNA-bound proteomes of three different mouse organs. The resulting organ atlases encompass more than 1300 RBPs active in brain, kidney or liver. Nearly a quarter (291) of these had formerly not been identified in cultured cells, with more than 100 being metabolic enzymes. Remarkably, RBP activity differs between organs independent of RBP abundance, suggesting organ-specific levels of control. Similarly, we identify systematic differences in RNA binding between animal organs and cultured cells. The pervasive RNA binding of enzymes of intermediary metabolism in organs points to tightly knit connections between gene expression and metabolism, and displays a particular enrichment for enzymes that use nucleotide cofactors. We describe a generically applicable refinement of the eRIC technology and provide an instructive resource of RBPs active in intact mammalian organs, including the brain.